Abstract
Background: There have been massive efforts on vaccine development against HIV-1 since its discovery. Various approaches have been taken to attention, including rational vaccine design, optimized delivery systems and heterologous regimen to eradicate the virus. DNA vaccines fundamentally induce host immune responses by genetically engineered plasmids encoding antigens and expressed in vivo without the need of the specific delivery system. Therefore, long-term endogenous antigen expression could be possible.
Objective: In this study, we aimed at evaluation and comparison of DNA and protein vaccine based on two forms of full and truncated HIV-1 p24-nef antigens by in silico design in BLALB/c.
Methods: The recombinant pcDNA3.1 harboring two sets of HIV-1 p24 and nef genes in truncated and full forms were generated and applied to immunize BALB/c along with the corresponding proteins via three different DNA/DNA, DNA/protein and protein/protein regimens.
Results: The results showed that the applied regimens could elicit strong immune responses in comparison with controls and the prim-boost DNA/protein regimen reached the highest immune induction (p < 0.05). Moreover, prime-boost approach was assessed more successfully in a qualitatively broad Th1 response induction. The truncated form of the antigens, p24(80-231 aa)-AAY- Nef (120-150), was evaluated more immunogenic in agreement with the in silico investigation.
Conclusion: The truncated form of p24-Nef was evaluated highly immunogenic specially when applied in prim-boost DNA/Protein regimen and could be investigated in other delivery systems and a proper animal model to achieve a therapeutic vaccine candidate against HIV-1.
Keywords: HIV-1, p24-Nef, DNA/protein prime-boost vaccine, therapeutic, in silico, vaccine.
Current Drug Delivery
Title:HIV-1 p24-nef DNA Vaccine Plus Protein Boost Expands T-Cell Responses in BALB/c
Volume: 18 Issue: 7
Author(s): Mona Sadat Larijani, Seyed Mehdi Sadat*, Azam Bolhassani, Arezoo Khodaie, Mohammad Hassan Pouriayevali and Amitis Ramezani*
Affiliation:
- Hepatitis, AIDS and Blood borne diseases Department, Pasteur Institute of Iran, Tehran,Iran
- Clinical Research Department, Pasteur Institute of Iran, Tehran,Iran
Keywords: HIV-1, p24-Nef, DNA/protein prime-boost vaccine, therapeutic, in silico, vaccine.
Abstract:
Background: There have been massive efforts on vaccine development against HIV-1 since its discovery. Various approaches have been taken to attention, including rational vaccine design, optimized delivery systems and heterologous regimen to eradicate the virus. DNA vaccines fundamentally induce host immune responses by genetically engineered plasmids encoding antigens and expressed in vivo without the need of the specific delivery system. Therefore, long-term endogenous antigen expression could be possible.
Objective: In this study, we aimed at evaluation and comparison of DNA and protein vaccine based on two forms of full and truncated HIV-1 p24-nef antigens by in silico design in BLALB/c.
Methods: The recombinant pcDNA3.1 harboring two sets of HIV-1 p24 and nef genes in truncated and full forms were generated and applied to immunize BALB/c along with the corresponding proteins via three different DNA/DNA, DNA/protein and protein/protein regimens.
Results: The results showed that the applied regimens could elicit strong immune responses in comparison with controls and the prim-boost DNA/protein regimen reached the highest immune induction (p < 0.05). Moreover, prime-boost approach was assessed more successfully in a qualitatively broad Th1 response induction. The truncated form of the antigens, p24(80-231 aa)-AAY- Nef (120-150), was evaluated more immunogenic in agreement with the in silico investigation.
Conclusion: The truncated form of p24-Nef was evaluated highly immunogenic specially when applied in prim-boost DNA/Protein regimen and could be investigated in other delivery systems and a proper animal model to achieve a therapeutic vaccine candidate against HIV-1.
Export Options
About this article
Cite this article as:
Larijani Sadat Mona, Sadat Mehdi Seyed *, Bolhassani Azam , Khodaie Arezoo, Pouriayevali Hassan Mohammad and Ramezani Amitis*, HIV-1 p24-nef DNA Vaccine Plus Protein Boost Expands T-Cell Responses in BALB/c, Current Drug Delivery 2021; 18 (7) . https://dx.doi.org/10.2174/1567201818666210101113601
DOI https://dx.doi.org/10.2174/1567201818666210101113601 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmaco-Therapeutic Challenges in Cancer Biology with Focus on the Immune- System Related Risk Factors
Current Pharmaceutical Design Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform
Current Radiopharmaceuticals Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Current Pharmaceutical Design Kinases as Drug Discovery Targets in Hematologic Malignancies
Current Molecular Medicine The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer
Current Drug Targets Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Effects of Natural Products on Mcl-1 Expression and Function
Current Medicinal Chemistry Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
Recent Patents on Anti-Cancer Drug Discovery Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design Expression and Function of the Transient Receptor Potential Ion Channel Family in the Hematologic Malignancies
Current Molecular Pharmacology Patent Selections
Recent Patents on DNA & Gene Sequences Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development
Current Medicinal Chemistry Renal Tubular Acidosis
Current Pediatric Reviews Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Mechanisms Underlying Chemotherapy-Induced Neurotoxicity and the Potential for Neuroprotective Strategies
Current Medicinal Chemistry